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Transcription Factor SIX5 Is Mutated in Patients
with Branchio-Oto-Renal Syndrome
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Dana J. Orten, William J. Kimberling, Richard J. H. Smith, Dominique Weil, Christine Petit,
Edgar A. Otto, Pin-Xian Xu,* and Friedhelm Hildebrandt*
Branchio-oto-renal syndrome (BOR) is an autosomal dominant developmental disorder characterized by the association
of branchial arch defects, hearing loss, and renal anomalies. Mutations in EYA1 are known to cause BOR. More recently,
mutations in SIX1, which interacts with EYA1, were identified as an additional cause of BOR. A second member of the
SIX family of proteins, unc-39 (SIX5), has also been reported to directly interact with eya-1 in Caenorhabditis elegans. We
hypothesized that this interaction would be conserved in humans and that interactors of EYA1 represent good candidate
genes for BOR. We therefore screened a cohort of 95 patients with BOR for mutations in SIX5. Four different heterozygous
missense mutations were identified in five individuals. Functional analyses of these mutations demonstrated that two
mutations affect EYA1-SIX5 binding and the ability of SIX5 or the EYA1-SIX5 complex to activate gene transcription.
We thereby identified heterozygous mutations in SIX5 as a novel cause of BOR.
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Branchio-oto-renal syndrome (BOR [MIM 113650]) is a
clinically heterogeneous autosomal dominant disorder
comprising branchial arch defects, hearing loss, and renal
anomalies. The syndrome has an estimated prevalence of
1 in 40,000 and accounts for ∼2% of profound deafness.1
Abnormal pinnae, cervical fistulas, pits, and/or cysts are
the most common branchial arch defects seen in patients,
whereas hearing loss can be conductive, sensorineural, or
mixed and often is associated with preauricular tags or
pits.2 Renal defects, which are estimated to be severe in
only 6% of patients, can include collecting system dupli-
cation, hypoplasia, cystic dysplasia, hydronephrosis, and
agenesis.3 The penetrance of the syndrome is highly var-
iable both between and within families. Heimler and Lie-
ber4 published a report on a large, four-generation kindred
containing 16 individuals with confirmed manifestations
of the syndrome. Of these, only four had abnormalities
of all three systems, whereas seven had branchial arch
and/or hearing defects but no reported renal abnormali-
ties. However, because only one of these individuals had
undergone a detailed renal evaluation, it is possible that
the incidence of renal defects in this kindred is higher
than reported.
In addition to being clinically heterogeneous, BOR also
displays genetic heterogeneity. Mutations in the EYA1
gene, the human ortholog of the eyes absent gene in Dro-
sophila, were the first cause of BOR to be identified after
the disease was linked to chromosome 8q13.3.5,6 Loss-of-
function alleles, including nonsense, frameshift, and
splice-site mutations, were found in 7 of 42 patients
screened by sequencing. In addition, deletions estimated
to span 6, 7, and 20 kb were identified in 3 of 21 patients
screened by Southern blot analysis. Although it was ini-
tially predicted that causative mutations would cluster in
the eyes absent homologous region (eyaHR), also known
as the EYA domain (ED) of EYA1,7 a large number of al-
terations distributed throughout the gene have since been
reported, including complex rearrangements involving
each of the 16 exons of the gene and multiple loss-of-
function and missense mutations in all exons, with the
exception of exons 1–3.8–11
EYA proteins are characterized by a divergent N-terminal
transactivation domain and the conserved C-terminal ED,
which mediates interactions with DNA-binding proteins
such as SIX1 and SIX2 (human orthologs of Drosophila
“sine oculis” [so]), thereby forming a potent transactiva-
tion complex.12,13 To determine whether mutation of res-
idues within the ED affects the ability of Eya1 to directly
interact with Six1 or Six2, Buller et al.12 performed GST
pull-down and yeast two-hybrid assays on five mutations.
Three ED constructs, each containing a single substituted
residue (E330K, S454P, and L472R), showed a reduction
in Eya1-Six binding in both assays, suggesting that these
residues are essential for direct Eya1-Six interaction. Mut-
suddi et al.14 used in vitro biochemical assays, in addition
to in vivo studies of Drosophila eye, to also test the loss of
function due to the S454P and L472R EYA1 mutations.
(Because a different isoform of EYA1 was used for amino
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Table 1. Clinical and Genetic Data on Five Patients with SIX5 Mutations
Patient Branchial Defect
Hearing
Loss Renal Defect
Nucleotide
Change
Amino Acid
Change
A441 PTR - DKB c.472GrA A158T
A477 CFB, HMR, PSR, PMR L, R DKB, f function c.886GrA A296T
A416 ND ND ND c.1093GrA G365R
A465 CFB - HKB c.1655CrT T552M
A500 CFB L, R AL, HKR c.1655CrT T552M
NOTE.— p absent,  p affected,  p more affected; L p left, R p right, B p bilateral; PT p
preauricular tag, DKp dysplastic kidneys, CFp cervical fistulae, HMp hemifacial microsomia, PSp preaur-
icular sinus, PM p pinna malformation, f function p diminished renal function, HK p hypoplastic kidneys,
A p agenesis; ND p no data available.
acid numbering by Mutsuddi et al., S454P and L472R are
described as S487P and L505R, respectively.) Both muta-
tions showed an approximately fivefold reduction in the
ability of the eya-so complex to transactivate. However,
coimmunoprecipitation studies showed that this reduc-
tion was not due to an inability of the complex to form,
as both mutant constructs were able to complex efficiently
with so.
Following the identification of EYA1 as the first BOR
gene, a number of reports on the exclusion of the 8q13
locus and mapping of additional BOR loci, such as the
BOS2 (branchiootic syndrome 2 [MIM %120502]) locus
on 1q31, were published.15–17 Most recently, we used a
large BOR kindred with 140 affected individuals to map
a third BOR locus (branchiootic syndrome-3 [MIM
608389]) to 14q21.3.18 Located within the 33-Mb critical
interval were three members of the SIX family of genes
(SIX1, SIX4, and SIX6). Mutation screening of these genes
in the family used to map the locus revealed a heterozy-
gous Y129C missense mutation in SIX1, with two further
mutations (delE133 and R110W) in three additional pa-
tients, confirming SIX1 as a second gene for BOR.19 Func-
tional analysis of these mutations demonstrated that the
R110W mutation, located in the SIX domain (SD), inter-
feres with formation of the Eya1-Six1 complex, whereas
the Y129C and delE133 mutations affect not only this
protein-protein interaction but also the ability of Six1 to
bind DNA.19
In 2004, the Caenorhabditis elegans interactome was pub-
lished, containing data on 14,000 direct protein-protein
interactions in the nematode identified by high-through-
put, yeast two-hybrid analysis.20 At the center of one of
the subnetworks made up of 175 interactions was C49A1.4
(eya-1), the ortholog of EYA1. In addition to the ortholog
of SIX1 (ceh-33), a second member of the SIX family of
proteins, SIX5 (unc-39/ceh-35), was also shown to directly
interact with eya-1 in the nematode. Because SIX5 has a
high degree of homology to SIX1 and directly interacts
with eya-1 in C. elegans, we considered it an excellent
candidate for mutation analysis in a cohort of patients
with BOR who did not have mutations in either EYA1 or
SIX1.
Patients.—The diagnosis of BOR was based on published
criteria.10 All samples were negative for EYA1 or SIX1 mu-
tations. This study was approved by the institutional re-
view boards of the University of Freiburg (303102) and
the University of Michigan Medical School (2004-0322,
HUM00003330). Patient samples were obtained after in-
formed consent was given.
Mutation analysis.—Primers were designed to amplify
each of the three exons and surrounding intronic se-
quence of SIX5. Standard PCR were performed, and se-
quencing was performed on an ABI capillary sequencer.
Sequence traces were analyzed using the Sequencher soft-
ware program (Gene Codes). Absence of sequence changes
in 150 European white control individuals was performed
by sequencing or, where possible, by digestion of the PCR
product with a restriction enzyme.
Generation of SIX5 constructs.—The human SIX5 full-
length cDNA was cloned by RT-PCR into either pGBKT7
vector for yeast two-hybrid assays or pcDNA3 vector for
cell-culture analysis. To introduce the same amino acid
substitutions found in patients with BOR into the human
SIX5 protein, PCR-based mutagenesis was performed us-
ing the QuickChange mutagenesis kit (Stratagene). Once
mutant colonies were identified, the plasmid DNA was
isolated and sequenced through the mutation-containing
region. Four mutant cDNAs (A158T, A296T, G365R, and
T552M) were constructed in the same manner in either
the pGBKT7 or the pcDNA3 vector.
Yeast two-hybrid assay.—The Matchmaker Two-Hybrid
System 3 (Clontech) was used for yeast interaction assays.
SIX5 was fused with the GAL4 DNA-binding domain of
pGBKT7 (GAL4 BD-SIX5). The Eya1 domain (Eya1D) re-
gion of Eya1 was fused with the GAL4 activation domain
of pGAD424 (GAL4 AD-Eya1D). Small scale LiAc cotrans-
formations of the plasmids into AH109 cells, colony-lift
filter assays, and liquid culture b-galactosidase assays were
performed as described in the Clontech protocols.
Luciferase assay.—The human embryonic kidney
HEK293 cell line and Cos-7 cells were cultured as de-
scribed elsewhere.12 The myogenin luciferase reporter
pGL3-6#MEF3 was used as a reporter. One microgram of
pGL3-6#MEF3 plasmid was cotransfected with 1 mg of
pcDNA3-SIX5 wild type (wtSIX5) or its mutant plasmids,
or 1 mg Eya1 alone, or both SIX5 and Eya1 together with
use of FuGENE 6 Transfection Reagent (Roche), according
to the manufacturer’s instructions. Cells were grown in
dishes 6 cm in diameter and were additionally cotrans-
fected with 0.25 mg of the cytomegalovirus (CMV) pro-
moter-b-galactosidase (pCMVb-gal) as an internal control.
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Figure 1. Four missense mutations in SIX5 identified in patients with BOR. A, A158T, A296T, and G365R mutations, present in
heterozygous form in a single patient. The T552M mutation was detected in patients A465 and A500. Sequences from the affected
individual are shown above sequences from healthy control individuals. Patient identifiers, nucleotide changes, and amino acid changes
are shown above the traces. B, SIX5 has an SD and a homeodomain (HD) characteristic of the SIX family of proteins at the N-terminus.
An activation domain has also been mapped to the C-terminus.21 The A158T mutation is located in the SIX domain; the remaining three
mutations are located between the HD and the activation domain.
Figure 2. Mutations in SIX5 affect SIX5-Eya1 binding. Yeast two-
hybrid assays were performed to test the effect of the mutations
on the ability of SIX5 to bind to Eya1. Cotransformation of GAL4BD-
SIX5 and GAL4AD-Eya1D leads to strong lacZ expression. An 12-
fold reduction in LacZ expression is seen when SIX5 proteins con-
taining an A158T or a T552M mutation are cotransformed with
Eya1D fusion proteins.
Forty-eight hours after transfection, cell extracts were pre-
pared and assayed for luciferase activities.
Mutation screening of SIX5 in 95 unrelated patients
with BOR revealed four different heterozygous missense
mutations in five individuals (table 1 and fig. 1). Individ-
ual A441, who has bilateral dysplastic kidneys and a right
preauricular tag but normal hearing, was found to carry
a c.472GrA substitution (amino acid change A158T). In-
dividual A477 has bilateral cervical fistulae; hemifacial mi-
crosomia; a preauricular sinus and pinna malformation
on the right side; hearing loss in both ears, with the right
ear more affected than the left; and bilateral renal dys-
plasia with diminished renal function. This patient was
found to have a c.886GrA transition (amino acid change
A296T). In individual A416, a c.1093GrA substitution
(amino acid change G365R) was found. In addition, a
c.1655CrT transition (amino acid change T552M) was
found in two individuals: A465, who has cervical fistulae
with hypoplastic kidneys, and A500, who has cervical fis-
tulae, moderate to severe hearing loss in both ears, and
left renal agenesis with a hypoplastic right kidney. All se-
quence changes were absent in 150 healthy control in-
dividuals. The phenotypes of the patients presented here
show a similarly high degree of variability, as seen in pa-
tients with BOR who had mutations in EYA1 or SIX1.10,19
Although the cohort of patients is small, there is no evi-
dence of a genotype-phenotype correlation associated
with SIX5 mutations.
To test whether any of the mutations identified in pa-
tients affect the ability of SIX5 to directly interact with
Eya1, yeast two-hybrid liquid b-galactosidase assays were
performed. Cotransformation of yeast with GAL4 BD-SIX5
and GAL4 AD-Eya1D constructs led to strong lacZ ex-
pression as a result of interaction between the two fusion
proteins (fig. 2). Introduction of mutations into the SIX5
construct showed varying levels of reduction in lacZ ex-
pression. A296T and G365R showed only a slight reduc-
tion in expression, whereas both A158T and T552M
showed a 12-fold reduction, indicating that these two res-
idues of SIX5 may be required for efficient binding with
EYA1.
To investigate what effect these mutations may have
on the ability of SIX5 or the Eya1-SIX5 complex to acti-
vate transcription, the myogenin luciferase reporter pGL3-
6#MEF3 was used. This construct contains six MEF3 sites
to which SIX proteins are known to bind.19,21 Transfection
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Figure 3. Mutations in SIX5 reduce its ability to activate tran-
scription of the MEF3 promoter. The myogenin luciferase reporter
pGL3-6#MEF3 was cotransfected with pcDNA3 vector containing
SIX5 or its mutants (A158T, A296T, G365R, and T552M), pFlag-
Eya1, or both the SIX5 and Eya1 plasmids together in HEK293
cells. Luciferase activity in the cell lysate was normalized with b-
galactosidase activity of pCMVb-gal as an internal control. The
activity at each data point is relative to that obtained by the
control pCMV vector. The mean fold activation from three inde-
pendent experiments (each performed in duplicate) is shown with
the standard deviation. A filled circle (•) indicates , com-P ! .002
pared with SIX5; an asterisk (*) indicates , compared withP ! .002
SIX5/Eya1 (one-way analysis of variance [ANOVA]).
of HEK293 cells with wtSIX5 resulted in an ∼7-fold in-
crease in luciferase activity compared with vector alone
(fig. 3). Transfection of the A296T and G365R mutant con-
structs alone did not result in a significant decrease in
luciferase reporter activity. However, the A158T and
T552M mutations resulted in significant decreases in lu-
ciferase activity when compared with wtSIX5. Decreases
were 50% for A158T and 25% for T552M. Coexpression
of wtSIX5 with Eya1 resulted in a 12-fold increase in lu-
ciferase activity. However, when each of the mutant SIX5
proteins was coexpressed with Eya1, the increase in activ-
ity was reduced to 52%, 80%, 70%, and 56% of that seen
for wtSIX5 with Eya1 for the A158T, A296T, G365R, and
T552M mutants, respectively. Although the reduction in
transcriptional activity is small for the A296T and G365R
mutants, these reductions are statistically significantwhen
compared with the activity seen on coexpression of
wtSIX5 with Eya1 (fig. 3). The results were reproducible
in three independent experiments, each performed in
duplicate.
In this study, we have identified heterozygous muta-
tions in SIX5 as a novel cause of BOR. SIX5 was considered
to be a good candidate gene for BOR, owing to its simi-
larity to SIX1, a known BOR gene,19 and data on C. elegans
on its direct interaction with eya-1,20 mutations of which
also cause BOR.6 Four different missense mutations were
identified in five patients from a cohort of 95 unrelated
individuals. Although it was not possible to perform seg-
regation analyses on these mutations, because DNA sam-
ples from family members were not available, the absence
of each mutation in a cohort of 150 healthy control in-
dividuals strongly suggests that these changes are disease-
causing mutations rather than nonpathogenic polymor-
phisms. This is confirmed by the functional studies of
Eya1-SIX5 interaction and reduced function in transcrip-
tional activation assays.
Unlike SIX1, SIX5 possesses an additional activation
domain (AD) at the C-terminus, which retains its trans-
activation function when fused to a GAL4 DNA-binding
domain.22 Consistent with this, our data show that ex-
pression of SIX5 alone is able to transactivate MEF3-re-
porter transcription in cultured cells (fig. 3). SIX5 is also
able to synergistically activate MEF3 reporter gene ex-
pression when coexpressed with Eya proteins21 (fig. 3).
Among the four mutations identified in the SIX5 protein,
the A158T mutation is located in the SD domain, while
the other three mutations are located between the HD and
AD domains (fig. 1B). Our results show that the SD mu-
tation A158T resulted in a reduction (50%) in reporter
activity in a yeast two-hybrid assay (fig. 2) and that this
reduction can be explained by a decrease in the Eya1-SIX5
complex formation. Interestingly, the luciferase assay
showed that the SD mutation (A158T) decreased the re-
porter activity in the absence of Eya1. Because the SD is
known to mediate not only protein-protein interaction
but also protein-DNA binding affinity through dimeriza-
tion,21,23,24 the reduction in reporter activity observed in
cultured cells without addition of Eya1 is likely caused by
the SD mutation affecting the formation of the SIX5-DNA
binding complex.
In contrast to A158T, the two mutations A296T and
G365R have no effect on the ability of SIX5 alone to
activate transcription but do affect the transcriptional ac-
tivity of the Eya1-SIX5 complex, to varying degrees. The
largest effect on coexpression was again seen for A158T
and the second largest for the T552M mutation. Because
the mutated T552M residue is near the C-terminal ac-
tivation domain, it may affect SIX5 transactivation
function.
It should be noted that the effect of SIX1 mutations19
was greater than that seen with the SIX5 mutations pre-
sented here. This may be in part because SIX5 itself is
transcriptionally active but also because, when transfected
together with Eya1, Eya2, or Eya3, the combination of Six5
with Eya3 showed the highest levels of activity on a my-
ogenin luciferase reporter: 8-fold activation compared
with the 4-fold activation seen with Six5 and Eya1.21
Therefore, although EYA1 and SIX5 do interact, there may
be some additional transcriptional activation through
EYA3.
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We have identified mutations in SIX5 as a new cause of
BOR. In addition, we provided evidence to support the
interaction between Eya1 and SIX5 and showed that mu-
tations of SIX5 compromise the interaction between the
two proteins, decreasing the transcriptional activity of the
Eya1-SIX5 complex.
Acknowledgments
We thank the patients and their families for their contribution.
We also thank Shrawan Kumar, Harold Bass, and Cor Cremers for
ascertainment of patient samples. This work was supported by
grants from the National Institutes of Health to F.H. (R01-
DK045345-01), P-X.X. (RO1 DC005824 and DK064640), and
C.H.C. (T32DK0655517-01). F.H. is the Frederick G. L. Huetwell
Professor of the Cure and Prevention of Birth Defects and a Doris
Duke Distinguished Clinical Scientist.
Web Resource
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for BOR, BOS2, and branchiootic syn-
drome-3 locus)
References
1. Fraser FC, Sproule JR, Halal F (1980) Frequency of the bran-
chio-oto-renal (BOR) syndrome in children with profound
hearing loss. Am J Med Genet 7:341–349
2. Weber KM, Kousseff BG (1999) “New” manifestations of BOR
syndrome. Clin Genet 56:306–312
3. Izzedine H, Tankere F, Launay-Vacher V, Deray G (2004) Ear
and kidney syndromes: molecular versus clinical approach.
Kidney Int 65:369–385
4. Heimler A, Lieber E (1986) Branchio-oto-renal syndrome: re-
duced penetrance and variable expressivity in four genera-
tions of a large kindred. Am J Med Genet 25:15–27
5. Kalatzis V, Abdelhak S, Compain S, Vincent C, Petit C (1996)
Characterization of a translocation-associated deletion de-
fines the candidate region for the gene responsible for bran-
chio-oto-renal syndrome. Genomics 34:422–425
6. Abdelhak S, Kalatzis V, Heilig R, Compain S, Samson D, Vin-
cent C, Weil D, Cruaud C, Sahly I, Leibovici M, et al (1997)
A human homologue of the Drosophila eyes absent gene un-
derlies branchio-oto-renal (BOR) syndrome and identifies a
novel gene family. Nat Genet 15:157–164
7. Abdelhak S, Kalatzis V, Heilig R, Compain S, Samson D, Vin-
cent C, Levi-Acobas F, Cruaud C, Le Merrer M, Mathieu M,
et al (1997) Clustering of mutations responsible for branchio-
oto-renal (BOR) syndrome in the eyes absent homologous re-
gion (eyaHR) of EYA1. Hum Mol Genet 6:2247–2255
8. Vincent C, Kalatzis V, Abdelhak S, Chaib H, Compain S, Helias
J, Vaneecloo FM, Petit C (1997) BOR and BO syndromes are
allelic defects of EYA1. Eur J Hum Genet 5:242–246
9. Vervoort VS, Smith RJ, O’Brien J, Schroer R, Abbott A, Ste-
venson RE, Schwartz CE (2002) Genomic rearrangements of
EYA1 account for a large fraction of families with BOR syn-
drome. Eur J Hum Genet 10:757–766
10. Chang EH, Menezes M, Meyer NC, Cucci RA, Vervoort VS,
Schwartz CE, Smith RJ (2004) Branchio-oto-renal syndrome:
the mutation spectrum in EYA1 and its phenotypic conse-
quences. Hum Mutat 23:582–589
11. Clarke JC, Honey EM, Bekker E, Snyman LC, Raymond RM
Jr, Lord C, Brophy PD (2006) A novel nonsense mutation in
the EYA1 gene associated with branchio-oto-renal/bran-
chiootic syndrome in an Afrikaner kindred. Clin Genet 70:
63–67
12. Buller C, Xu X, Marquis V, Schwanke R, Xu PX (2001) Mo-
lecular effects of Eya1 domain mutations causing organ de-
fects in BOR syndrome. Hum Mol Genet 10:2775–281
13. Pignoni F, Hu B, Zavitz KH, Xiao J, Garrity PA, Zipursky SL
(1997) The eye-specification proteins So and Eya form a com-
plex and regulate multiple steps in Drosophila eye develop-
ment. Cell 91:881–891
14. Mutsuddi M, Chaffee B, Cassidy J, Silver SJ, Tootle TL, Rebay
I (2005) Using Drosophila to decipher how mutations asso-
ciated with human branchio-oto-renal syndrome and optical
defects compromise the protein tyrosine phosphatase and
transcriptional functions of eyes absent. Genetics 170:687–
695
15. Kumar S, Deffenbacher K, Marres HA, Cremers CW, Kimber-
ling WJ (2000) Genomewide search and genetic localization
of a second gene associated with autosomal dominant bran-
chio-oto-renal syndrome: clinical and genetic implications.
Am J Hum Genet 66:1715–1720
16. Kumar S, Marres HA, Cremers CW, Kimberling WJ (1998)
Autosomal-dominant branchio-otic (BO) syndrome is not al-
lelic to the branchio-oto-renal (BOR) gene at 8q13. Am J Med
Genet 76:395–401
17. Stratakis CA, Lin JP, Rennert OM (1998) Description of a large
kindred with autosomal dominant inheritance of branchial
arch anomalies, hearing loss, and ear pits, and exclusion of
the branchio-oto-renal (BOR) syndrome gene locus (chro-
mosome 8q13.3). Am J Med Genet 79:209–214
18. Ruf RG, Berkman J, Wolf MT, Nurnberg P, Gattas M, Ruf EM,
Hyland V, Kromberg J, Glass I, Macmillan J, et al (2003) A
gene locus for branchio-otic syndrome maps to chromosome
14q21.3-q24.3. J Med Genet 40:515–519
19. Ruf RG, Xu PX, Silvius D, Otto EA, Beekmann F, Muerb UT,
Kumar S, Neuhaus TJ, Kemper MJ, Raymond RM Jr, et al
(2004) SIX1 mutations cause branchio-oto-renal syndrome by
disruption of EYA1-SIX1-DNA complexes. Proc Natl Acad Sci
USA 101:8090–8095
20. Li S, Armstrong CM, Bertin N, Ge H, Milstein S, Boxem M,
Vidalain PO, Han JD, Chesneau A, Hao T, et al (2004) A map
of the interactome network of the metazoan C. elegans. Sci-
ence 303:540–543
21. Ohto H, Kamada S, Tago K, Tominaga SI, Ozaki H, Sato S,
Kawakami K (1999) Cooperation of Six and Eya in activation
of their target genes through nuclear translocation of Eya.
Mol Cell Biol 19:6815–6824
22. Kawakami K, Sato S, Ozaki H, Ikeda K (2000) Six family
genes—structure and function as transcription factors and
their roles in development. Bioessays 22:616–626
23. Pham YC, Man N, Holt I, Sewry CA, Pall G, Johnson K, Morris
GE (2005) Characterisation of the transcription factor, SIX5,
using a new panel of monoclonal antibodies. J Cell Biochem
95:990–1001
24. Harris SE, Winchester CL, Johnson KJ (2000) Functional anal-
ysis of the homeodomain protein SIX5. Nucleic Acids Res 28:
1871–1878
